科濟藥業-B(02171.HK)引入珠海軟銀欣創投資以加速通用型CAR-T細胞產品在中國內地進程
格隆匯2月26日丨科濟藥業-B(02171.HK)公吿,公司若干附屬公司與珠海橫琴軟銀欣創股權投資管理企業(有限合夥)("珠海軟銀欣創")旗下管理的基金("投資者")達成協議。根據該等協議,投資者同意以現金對價人民幣8000萬元認購優愷澤生物醫藥(上海)有限公司新增註冊資本,佔優愷澤增資後註冊資本的8%。本次增資完成後,公司於優愷澤的權益將由100%稀釋至92%。
優愷澤是一家在中國內地專注於利用通用型CAR-T細胞療法治療血液瘤的新藥研發公司。根據該等協議,優愷澤獲得本公司治療多發性骨髓瘤、漿細胞白血病的通用型BCMACAR-T細胞產品以及治療B細胞腫瘤的通用型CD19/CD20CAR-T細胞產品(不包括治療自身免疫性疾病的適應證)在中國內地的研發、生產與商業化的獨家權利。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.